Haemonetics Corporation (HAE)

NYSE: HAE · IEX Real-Time Price · USD
62.54
1.77 (2.91%)
May 25, 2022 4:00 PM EDT - Market closed
Market Cap3.20B
Revenue (ttm)953.22M
Net Income (ttm)22.59M
Shares Out51.11M
EPS (ttm)0.84
PE Ratio74.45
Forward PE21.10
Dividendn/a
Ex-Dividend Daten/a
Volume514,734
Open60.25
Previous Close60.77
Day's Range60.25 - 63.55
52-Week Range43.50 - 75.34
Beta0.43
AnalystsBuy
Price Target72.42 (+15.8%)
Earnings DateMay 10, 2022

About HAE

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides autom...

IndustryHealth Care Equipment & Supplies
IPO DateMay 9, 1991
CEOChristopher Simon
Employees2,708
Stock ExchangeNYSE
Ticker SymbolHAE
Full Company Profile

Financial Performance

In 2021, Haemonetics's revenue was $870.46 million, a decrease of -11.94% compared to the previous year's $988.48 million. Earnings were $79.47 million, an increase of 3.85%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for HAE stock is "Buy." The 12-month stock price forecast is 72.42, which is an increase of 15.80% from the latest price.

Price Target
$72.42
(15.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Here's Why Investors Should Retain Haemonetics (HAE) For Now

Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.

2 days ago - Zacks Investment Research

Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up

Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.

2 weeks ago - Zacks Investment Research

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Haemonetics to Host Investor Day Event on June 29, 2022

BOSTON , May 10, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that it will host an Investor Day in Boston on Wednesday, June 29, 2022 beginning at 10:00 AM EDT. Members of Haemonet...

2 weeks ago - PRNewsWire

Haemonetics 4th Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website

Financial release accessible online BOSTON , May 10, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2022, which ended April 2, 20...

2 weeks ago - PRNewsWire

3 Medical Product Stocks Set to Beat on Earnings This Season

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.

Other symbols:ABTALCCGCISRG
2 weeks ago - Zacks Investment Research

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Here's Why You Should Hold on to Haemonetics (HAE) For Now

Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.

1 month ago - Zacks Investment Research

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2022 Results: May 10, 2022

BOSTON, April 6, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2022 financial results at 6:00 am EDT on Tuesday, May 1...

1 month ago - PRNewsWire

Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay

Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.

1 month ago - Zacks Investment Research

Haemonetics Appoints James D'Arecca Chief Financial Officer

BOSTON , March 21, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective A...

2 months ago - PRNewsWire

Haemonetics (HAE) Up 4.4% Since Last Earnings Report: Can It Continue?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.

2 months ago - Zacks Investment Research

Haemonetics to Present at Raymond James 43rd Annual Institutional Investors Conference

BOSTON, Feb. 23, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 43rd Annu...

3 months ago - PRNewsWire

Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss

Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.

3 months ago - Zacks Investment Research

Why Haemonetics Shares Are Trading Higher Today?

Haemonetics Corporation HAE posted Q3 FY22 sales of $259.77 million, +8% Y/Y, missing the consensus of $ $266.74 million. Organic revenue was down 0.8%.

3 months ago - Benzinga

Haemonetics (HAE) Q3 Earnings Beat Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 12% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Haemonetics 3rd Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website

BOSTON, Feb. 8, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal 2022, which ended January 1, 2022, are available on its Investor Re...

3 months ago - PRNewsWire

Should You Buy Haemonetics (HAE) Ahead of Earnings?

Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 months ago - Zacks Investment Research

Haemonetics (HAE) Expected to Beat Earnings Estimates: Should You Buy?

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2022 Results: February 8, 2022

BOSTON, Jan. 5, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, Februar...

4 months ago - PRNewsWire

Here's Why You Should Retain Haemonetics (HAE) Stocks for Now

Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.

5 months ago - Zacks Investment Research

Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows

Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.

6 months ago - Zacks Investment Research

Why Haemonetics Stock Dived by 15% Today

The company broadly meets expectations for its Q2 2022 but trims its full-year guidance.

6 months ago - The Motley Fool

Haemonetics (HAE) Lags Q2 Earnings and Revenue Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of -4.76% and -2.44%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research